病毒性肝炎受体导向药物L－HSA－Ara　AMP的导向性实验

Experimental Studies on Viral Hepatitis Receptor-targeted Drug L-HSA-Ara AMP

选用乳糖化人血清白蛋白（Ｌ－ＨＳＡ）为载体，与单磷酸阿糖腺苷（Ａｒａ－ＡＭＰ）交联成乳糖化人血清白蛋白单磷酸阿糖腺苷（Ｌ－ＨＳＡ－Ａｒａ－ＡＭＰ）交联物，观察了１２５Ｉ标记的该交联物在小鼠体内的分布。结果，１２５Ｉ－Ｌ－ＨＳＡ－ＨＳＡ及１２５Ｉ－Ｌ－ＨＳＡ－ＡｒａＡＭＰ在肝脏内的含量明显高于其他各脏器，前者在肝脏含量最高为第３ｄ，后者为第１ｄ，在第７ｄ仍有一定浓度，二者次于肝脏含量的组织均为肾脏和血液。

Lactosaminated Human Serum Albumin (L-HSA) was used as a carrier and coupled to Arabinoside adenine monophosphate (Ara AMP).The distribution of 125I-labelled L-HSA-Ara AMP conjugate in mice was observed.The results indicate;both the radioactivities of non conjugated 125I-L-HSA and conjugated 125I-L-HSA-Ara AMP were higher in liver than in other organs.Radioactivities of 125I-L-HSA in liver were the highest on the third day after injection.Radioactivities of 125I-L-HSA-Ara AMP in liver were the highest on the first day after injection.Radioactivities of both drugs could still be measured on the seventh day after injection.Radioactivities of both drugs in kidney and blood came secondly.